Symphony Thrombectomy System in the Treatment of Pulmonary Embolism

What is the Purpose of this Study?

This study focuses on individuals who are scheduled to undergo a thrombectomy (procedure to remove a blood clot using a tube) to treat their pulmonary embolism (blood clot in the lung). The purpose of the study is to evaluate the safety and effectiveness of the Symphony Thrombectomy System for the treatment of acute pulmonary embolism; the device will be used to remove blood clots in the lung. The U.S. Food and Drug Administration (FDA) has approved the Symphony Thrombectomy System to treat patients with deep vein thrombosis or blood clots in the extremities (legs), but its use in this study is experimental.

Eligibility

1. CTA evidence of acute PE within ≤14 days
2. Clinical signs and symptoms consistent with acute PE.
3. Systolic BP ≥90 mmHg with evidence of dilated RV with an RV/LV ratio \>0.9 (based on Investigator's assessment of RV/LV ratio)
4. Stable heart rate \<130 BPM prior to procedure

Inclusion Criteria:

1. CTA evidence of acute PE within ≤14 days
2. Clinical signs and symptoms consistent with acute PE.
3. Systolic BP ≥90 mmHg with evidence of dilated RV with an RV/LV ratio \>0.9 (based on Investigator's assessment of RV/LV ratio)
4. Stable heart rate \<130 BPM prior to procedure
5. Subject is between 18 and 80 years of age
6. Subject is willing to sign an IRB-approved informed consent form
7. Subject is willing and able to comply with protocol follow-up

Exclusion Criteria:

1. Thrombolytic use within 14 days of baseline CTA
2. International Normalized Ratio (INR) \>3
3. Platelets \<100,000/µL
4. Kidney dysfunction as confirmed by serum creatinine \>1.8 mg/dL or GFR \<45 mL/min
5. Hematocrit \<28% or hemoglobin \<9 g/dL
6. Systolic BP \<90 mmHg for 15 min or requirement of inotropic support to maintain systolic BP ≥90 mmHg any time after admission
7. Experienced cardiac arrest
8. Has left bundle branch block
9. Known bleeding diathesis or coagulation disorder
10. Presence of intracardiac lead in the right ventricle or right atrium
11. Presence of intracardiac thrombus
12. Major trauma within the past 14 days
13. Cardiovascular or pulmonary surgery within last 7 days
14. Known serious, uncontrolled sensitivity to radiographic agents
15. Contraindication to anticoagulants, i.e., heparin or alternative
16. Patient on extracorporeal membrane oxygenation (ECMO)
17. Cancer requiring active chemotherapy
18. Heparin-induced thrombocytopenia (HIT)
19. Pulmonary hypertension with peak pulmonary artery pressure \>70 mmHg by right heart catheterization.
20. History of chronic severe pulmonary hypertension, and/or chronic left heart disease with left ventricular ejection fraction ≤30%
21. Life expectancy \<90 days as determined by investigator
22. Pregnant or nursing
23. COVID-19 positive at hospital admission
24. Current participation in another investigational study
25. Evidence such as imaging or other that suggests the subject is not appropriate for this procedure (e.g., target vessel size is too small to accommodate 16F or 24F catheters).

Show less

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

SYMPHONY-PE Clinical Study: Evaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism

Study Details

Disease Type/Condition

Other

Principal Investigator

Lipshutz, H

Co-Investigators

Marc L. Friedman, Oren Friedman, Richard Van Allan, Suhail Dohad, Yuri Matusov

Age Group

Adult

Phase

N/A

IRB Number

STUDY00002759

ClinicalTrials.gov ID

NCT06062329

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

clinicaltrials@cshs.org